PDCD1 and colorectal carcinoma: However, despite the widespread use of anti-PD-1 and anti-PD-L1 antibodies as ICIs in CRC immunotherapy, their effectiveness is limited by the fact that most patients develop primary or acquired resistance during treatment (3, 5).